Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 20 de 578 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]
2. Cita con resumen
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH, ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003. [Ref.ID 100910]
3.Enlace a cita original Cita con resumen
Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Espposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, Valgimigli M, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ 2016;354:i4935. [Ref.ID 100794]
4. Cita con resumen
Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009. [Ref.ID 99531]
5.
Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AGG, Hasselblad V, Ortel TL, for the BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-33. [Ref.ID 99509]
6.Enlace a cita original Cita con resumen
Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA, for the CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-86. [Ref.ID 99497]
7.Tiene citas relacionadas Cita con resumen
Brotman DJ, Streiff MB. Overuse of bridging anticoagulation for patients with venous thromboembolism. First, do no harm. JAMA Intern Med 2015;175:julio. [Ref.ID 99097]
8.Tiene citas relacionadas Cita con resumen
Clark NP, Witt DM, Davies LE, Saito EM, McCool KH, Douketis JD, Metz KR, Delate T. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med 2015;175:1163-8. [Ref.ID 99096]
9.Tiene citas relacionadas Cita con resumen
Han Y, Guo J, Zheng Y, Zang H, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li Y, Xu B, Stone GW, for the BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA 2015;313:1336-46. [Ref.ID 99015]
10.Tiene citas relacionadas
Cavender MA, Faxon DP. Can BRIGHT restore the glow of bivalirudin?. JAMA 2015;313:1323-4. [Ref.ID 99014]
11. Cita con resumen
Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH, for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58. [Ref.ID 98362]
14. Cita con resumen
Llop R. Fármacos y alopecia. Formación Médica Continuada en Atención Primaria 2014;21:293-7. [Ref.ID 97542]
15.Tiene citas relacionadas
Anónimo. New oral anticoagulants for acute venous thromboembolism. JAMA 2014;311:731-2. [Ref.ID 97143]
16.Tiene citas relacionadas
Di Nisio M, Middeldorp S. Treatment of lower extremity superficial thrombophlebitis. JAMA 2014;311:729-30. [Ref.ID 97142]
17.Tiene citas relacionadas
Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA 2014;311:717-28. [Ref.ID 97141]
18.Tiene citas relacionadas
Mehta SR. Balancing thrombotic events and bleeding in primary PCI. N Engl J Med 2013;369:2263-5. [Ref.ID 96613]
19.Tiene citas relacionadas Cita con resumen
Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Berg JT, van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, for the EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-17. [Ref.ID 96610]
20.Tiene citas relacionadas Cita con resumen
Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, Tobias JH, Vernon K, Blom AW, on behalf of the National Joint Registry for England Wales and Northern Ireland. 90-day mortality after 409 096 total hip replacements for osteoarthritis, from the National Joint Registry for England and Wales: a retrospective analysis. Lancet 2013;382:1097-104. [Ref.ID 96311]
Seleccionar todas
 
 1 a 20 de 578 siguiente >>